|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/36 | |
| C07K 14/16 | |||
| C07K 14/745 |
| (11) | Patento numeris | 2680875 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12707095.1 |
| Europos patento paraiškos padavimo data | 2012-03-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-01-08 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-10-23 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2012/053619 |
| Data | 2012-03-02 |
| (87) | Numeris | WO 2012/117091 |
| Data | 2012-09-07 |
| (30) | Numeris | Data | Šalis |
| 11156682 | 2011-03-02 | EP | |
| 201161449254 P | 2011-03-04 | US |
| (72) |
HILDEN, Ida, DK
PESCHKE, Bernd, DK
BREINHOLT, Jens, DK
KOFOD-HANSEN, Mikael, DK
|
| (73) |
Novo Nordisk Health Care AG,
Thurgauerstrasse 36/38 8050 Zürich,
CH
|
| (54) | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS |
| COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS |